IR Press releases 2024-07-08

Gradientech announces outcome of directed issue of shares

Gradientech AB (publ) ("Gradientech" or the "Company") announces that the Company's directed issue of shares to a limited number of existing shareholders (the "Issue"), in which the subscription period ended on July 4, 2024, has ended. The final count shows that 3,109,849 shares were subscribed. Through the Issue, Gradientech will receive proceeds of approximately SEK 22.1 million before deduction of issue costs.

On July 5, 2024, the Board of Directors of Gradientech AB (publ) resolved through two separate resolutions to issue a maximum of 3,109,849 shares in total, without preferential rights for existing shareholders. Of these, 916,138 shares are subject to approval by the subsequent extraordinary general meeting. A total of 3,109,849 shares have been subscribed.

Number of shares and share capital

The issue provides Gradientech with approximately SEK 22.1 million before issue costs. As a result of the issue, the Company’s share capital may increase by a maximum of SEK 310,984.90 to a total of SEK 2,707,060.20 and the total number of shares may increase by 3,109,849 shares to 27,070,602 shares.



Redeye is acting as financial advisor and Advokatfirman Lindahl KB is acting as legal advisor to Gradientech in connection with the directed issue.


For further information, please contact:

Urban Adolfsson, CFO Gradientech

Tel: +46 70 820 72 09



About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden.
Visit for more information.